Supernus Pharmaceuticals, Inc. (0LB2.L) LSE

46.34

+0.408(+0.89%)

Updated at September 08 04:53PM

Currency In USD

Valuation

Market Cap1.99B
Enterprise Value1.96B
P/E Ratio40.01
PEG Ratio11.3
Price/Sales Ratio3.88
Price/Book Ratio2.43
Enterprise/Revenue3.71
Enterprise/EBITDA14.88

Fiscal Year

Fiscal YearDecember 31, 2024
Most Recent QuarterJune 30, 2025

Profitability

Profit Margin0.1
Operating Margin0.09

Management Effectiveness

Return On Assets0.05
Return On Equity0.06

Income Statement

Revenue661.82M
Revenue/Share11.87
Gross Profit583.91M
EBITDA178.28M
Net Income73.86M
Diluted EPS1.32

Balance Sheet

Total Cash522.6M
Total Cash/Share9.33
Total Debt31.77M
Total Debt/Equity0.03
Current Ratio2.58
Book Value Per Share18.99

Price History

52-Week Change37.79
52-Week High46.47
52-Week Low22.54
Moving Average 50 Days27.93
Moving Average 200 Days29.84

Statistics

Average Volume83
Shares Outstanding55.63M
% Held by InstitutionsN/A

Dividend And Splits

Trailing Annual Dividend Rate0
Trailing Annual Dividend Yield0
Payout Ratio0
Last Split FactorN/A
Last Split DateN/A